Fame and Mortality: Evidence from a Retrospective Analysis of Singers
November 26, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Ocrevus Zunovo
Synonyms :
ocrelizumab/hyaluronidase-ocsq
Class :
Brand Name :
Ocrevus Zunovo
Synonyms :
ocrelizumab/hyaluronidase-ocsq
Class :
Adult
ocrelizumab/hyaluronidase
Solution
920mg/23ml
Not determined
Ocrelizumab is a humanized monoclonal antibody that targets CD20 on B cells. They are involved in the immune response to damage the nervous system.
Hyaluronidase enzyme breaks down hyaluronic acid in the extracellular matrix to increase tissue permeability for better drug absorption.
Frequency defined:
>10%:
Occurrence within 24 hr after injection
Erythema, pain, swelling, pruritus
Occurrence during injection
Headache, nausea
Post marketing Reports
Immune-mediated colitis
Serious herpes infections, hepatitis B virus reactivation
Progressive multifocal leukoencephalopathy
None
Contraindications:
Hypersensitivity
History of life-threatening infusion reaction to ocrelizumab
Cautions:
Infusion Reactions
Hepatitis B Virus Reactivation
Malignancies
Immunization
Pregnancy category: N/A
Lactation: Excretion of the drug into the human breast milk is unknown
Pregnancy categories:
Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester.
Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.
Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women.
Category N: There is no data available for the drug under this category.
Ocrelizumab targets CD20 on B lymphocytes to induce lysis through binding with the cell surface of antigen.
Hyaluronidase breaks down hyaluronic acid in matrix to improve drug absorption and tissue permeability.
Pharmacodynamics:
Ocrelizumab activates immune cells to target CD20-bound antibodies and destroy B-cells.
Hyaluronidase improves distribution which breaks down hyaluronic acid at injection site to enhance absorption and systemic distribution.
Pharmacokinetic:
Absorption:
It has bioavailability up to 81% with SC route.
Distribution:
It is distributed throughout the body with 2.78 L as volume of distribution.
Metabolism:
It is not metabolized with cytochrome P450 enzymes pathways.
Excretion and elimination:
It has half-life of 20 days and clearance up to 0.17 L daily.
Administration:
It is administered subcutaneously in the injection form.
Patient information leaflet:
Generic Name: ocrelizumab/hyaluronidase-ocsq
Why do we use ocrelizumab/hyaluronidase-ocsq?
Ocrelizumab & hyaluronidase-ocsq is a combination drug used to treat Multiple Sclerosis.
It should be administered two times in a year as subcutaneous injection in relapsing and progressive form of Multiple Sclerosis.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
